Publications:

1. Singh B, Sharan R, Escobedo R, Shivanna V, Dick, E.J.Jr., Hall-Ursone S, Arora G,Alvarez X, Kaushal D and Mehra S. Inhibition of the immunoregulator IDO improves the quality of immune responses and is safe and efficacious for concurrent use with antiretroviral therapy as a therapeutic in the setting of Mtb/HIV co-infection. JCI Insight. 2024;9(15):e179317. https://doi.org/10.1172/jci.insight.179317.

2. Singh B, Moodley C, Singh DK, Escobedo R, Sharan S, Arora G, Ganatra SG, Shivanna V, Gonzalez O, Ursone SH, Dick EJ Jr, Kaushal D, Alvarez X, Mehra S. Inhibition of Indoleamine dioxygenase leads to better control of tuberculosis adjunctive to Chemotherapy. JCI Insight. 2023;8(2):e163101. https://doi.org/10.1172/jci.insight.163101

3. Gough M, Singh DK, Singh B, Kaushal D and Mehra S. System-wide identification of myeloid markers of TB disease and HIV-induced reactivation in the macaque model of Mtb infection and Mtb/SIV co-infection. Frontiers in Immunology, 2022. https://doi.org/10.3389/fimmu.2022.777733

4. Singh B, Singh DK, Ganatra S, Khader S, Schlesinger LS, Kaushal D, Mehra S.Myeloid-derived suppressor cells mediate T cell dysfunction in nonhuman primate TB granulomas. mBIO (2021). https://doi.org/10.1128/mbio.03189-21.

5. Singh DK, Aladyeva E, Das S, Singh B, Esaulova E, Swain A, Ahmed M, Cole J, Moodley C, Mehra S, Schlesinger LS, Artyomov MN, Khader SA, Kaushal D. Myeloid cell interferon responses correlate with clearance of SARS-CoV-2. Nature communications 13, Article number: 679 (2022). DOI: 10.1038/s41467-022-28315-7.

6. Sharan R, Ganatra SR, Bucsan AN, Cole J, Singh DK, Alvarez X, Gough M, Alvarez C, Blakley A, Ferdin J, Thippeshappa R, Singh B, Escobedo B, Shivanna V, Dick EJ, Ursone SH, Khader S, Mehra S, Rengarajan J, Kaushal D. Impact of timing of antiretroviral therapy on LTBI reactivation in TB/SIV coinfection model. Journal of Clinical Investigation, 2021 Dec 2;e153090. doi: 10.1172/JCI153090.

7. Rosa BA, Ahmed M, Singh DK, Alberto J, Cole J, Álvarez LA, Rodríguez TS, Singh B, Gonzalez O, Carrion R Jr., Schlesinger LA, Martin J, Zúñiga J, Mitreva M, Kaushal D, Khader SA. IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection. Communications Biology. 4, 29 (2021). https://doi.org/10.1038/s42003-021-01829-4.

8. Cronan MR, Hughes EJ, Brewer WJ, Viswanathan G, Hunt EG, Singh B, Mehra S, Oehlers SH, Gregory SG, Kaushal D, Tobin DM. A non-canonical type 2 immune response coordinates tuberculous granuloma formation and epithelialization. Cell,Volume 184, Issue 7, 2021, Pages 1757-1774.e14, ISSN 0092-8674, https://doi.org/10.1016/j.cell.2021.02.046.

9. Singh DK, Singh B, Ganatra SR et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nature Microbiology. 6, 73–86 (2021). https://doi.org/10.1038/s41564-020-00841-4.

10. Esaulova E, Das S, Singh DK, Choreño-Parra JA, Swain A, Arthur L, Javier Rangel-Moreno, Ahmed M, Singh B, Gupta A, Fernández-López LA, Garcia-Hernandez ML, Bucsan A, Moodley C, Mehra S, García-Latorre E, Zuniga J, Atkinson J, Kaushal D, Artyomov MN, and Khader SA. The immune landscape in tuberculosis reveals populations linked to disease and latency. Cell Host & Microbe, Volume 29, Issue 2, 2021, Pages 165-178.e8, ISSN 1931-3128, https://doi.org/10.1016/j.chom.2020.11.013.

11. Ganatra SR, Bucşan AN, Alvarez X, Kumar S, Chatterjee A, Quezada M, Fish A, Singh DK, Singh B, Sharan R, Lee TH, Shanmugasundaram U, Velu V, Khader SA, Mehra S,Rengarajan J, and Kaushal D. Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis HIV coinfection model. The Journal of Clinical Investigation. 2020 Oct 1; 130(10): 5171–5179. doi: 10.1172/JCI136502.

12. Gupta A, Saqib M, Singh B, Pal L, Nishikanta A, Bhaskar S. M. tuberculosis Specific Protective Memory T-cell Response in Airway Luminal Compartment Post Intranasal Vaccination with Mycobacterium indicus pranii. Frontiers in Immunology, 2019; 10: 2359.  doi: 10.3389/fimmu.2019.02359.

13. Singh B, Saqib M, Chakraborty A, Bhaskar S. Lipoarabinomannan from Mycobacterium indicus pranii shows immunostimulatory activity and induces autophagy in macrophages. PLoS One.  2019 Oct 24;14(10):e0224239. doi: 10.1371/journal.pone.0224239. eCollection 2019.

14. Saqib M, Khatri R, Singh B, Gupta A, Bhaskar S. Cell wall fraction of Mycobacterium indicus pranii (MIP) shows potential Th1 adjuvant activity. International Immunopharmacology. 2019 May; 70:408-416. doi: 10.1016/j.intimp.2019.02.049. Epub 2019 Mar 8.

15. Singh B, Saqib M, Gupta A, Kumar P, Bhaskar S. Autophagy induction by Mycobacterium indicus pranii promotes Mycobacterium tuberculosis clearance from RAW 264.7 macrophages. PLoS One. 2017 Dec 13;12(12):e0189606.

16. Saqib M, Khatri R, Singh B, Gupta A, Kumar A, Bhaskar S. Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis. Tuberculosis (Edinb). 2016;101:164-73.